Review and summarize the characteristics of national collection and speculation a new round of trend!

Medicine Network May 28 - The State Council of the Central Committee of the Communist Party of China (CPC) issued the Opinions on Deepening the Reform of the Medical Security System, noting that the reform of the centralized band procurement system for pharmaceutical and medical supplies should be deepened, emphasizing the leading role of centralized quantity procurement in medical reformFrom the 4 plus 7 pilot (hereinafter referred to as the pilot), to the 25 provincial and municipal unioncentralized procurement (hereinafter referred to as the alliance procurement), to the second batch of centralized procurement of national drugs (hereinafter referred to as collection II), the third batch (hereinafter referred to as collection III), generic drugs, the national centralized band procurement has gradually become the normat a pilot press conference4 and 7, the head of the pilot office said: "The purpose of the pilot procurement of drugs centralized by the state is to enable the people to use higher-quality drugs at relatively low prices." "
1Unlike Europe and the United States, China has not yet achieved the "patent cliff"the overall low quality level of generic drugs, it is difficult to compete fairly with the original drug at the same quality level, the price of the original research drug has been significantly higher for a long time, and the "patent cliff" has not occurred in China2Three progressive collectionfrom "pilot varieties, pilot cities", to "do not change the procurement varieties, expand the scope of urban procurement", to "procurement varieties change, national collection", step by step, to promote the process of maturity, norms, enhance enterprises and the public from the phenomenon to the essence of the understanding3This year, the range of collection varieties will continue to expand
continue to promote the collection process of two aspects: narrow ingenthethethethethethethes of the price gap between different enterprises of the same common name;the future, the ultimate goal of centralized drug procurement will be not only non-patented drug price reduction, original research drugs and exclusive high-quality high-demand drugs will also be the normal centralized procurement(1) participating in the enterprise surge
pilot participation enterprises are unknown, the alliance procurement of 77 participating enterprises, collection II directly soared to 122The increase in the number of participating enterprises, on the one hand, reflects the consistency of generic drug evaluation results highlighted, the large increase in over-evaluation enterprises, on the other hand, shows that the country's influence of collection and harvest ingress, enterprise awareness is positive(2) more beneficiary enterprisesthe pilot selection of 25 enterprises, the alliance procurement of 45, set pick IN 77, the number of enterprises increased, so that more enterprises benefit from the collection(3) the selected varieties gradually increased
from the pilot, alliance procurement to collection II, the increase of the selected varieties is not large, only increased by 7, but is of great significance, the collection of II logo drug national collection model formed(1) Coverage and use of drug demandcollection pilot and alliance procurement have not formed a policy document, the pilot coverage of 4 and 7 cities of public medical institutions, the alliance procurement of drug demand conditions unchanged, the scope of expansion of 25 provinces and cities, but on the day of the announcement of the results of the alliance procurement, September 30, 2019, "national medical security bureau and other nine departments on the national organization drug centralized procurement and use of the pilot expansion of the regional scope of implementation opinions", notice release, logo collection model to do a good job of collectioncollection II, clear lying that the country's publicand military hospitals must participate, private hospitals andto participate voluntarilyIndicates that the Joint Procurement Office shall determine the agreed procurement volume according to 50%-80% of the total procurement demand according to the number of selected enterprises, and implement the band purchase(2) The scope of the drug variety is clear
pilot and alliance procurement to identify the original research drugs, reference preparations and through consistency evaluation of generic drugs Determine 25 varieties, specify specifications and agreed purchase volume collection II requires through consistency evaluation of generic drugs, focusing on the selection of more competitive varieties (large varieties, large areas), taking into account the clinical efficacy of drugs, adverse reactions, batch stability and other factors (3) the first year of procurement volume and procurement cycle pilot is new, so in the time to consider the cycle of one year, taking into account the situation varies from place to place, there is no provision for procurement volume, take the form of local reporting Therefore, by the end of 2019, the pilot area average procurement implementation progress of 183%, has significantly exceeded the agreed procurement volume, it is necessary to make clear that this part is not incremental Alliance procurement of selected enterprises and procurement volume innovation methods, corresponding to 1 / 50%, 2 / 60%, 3 / 70%, the winning enterprises and procurement cycle corresponding to no more than 2 / 1 year, 3 / 2 years, the procurement cycle can be extended by one year depending on the situation collection II basically adopts the alliance procurement model, the procurement volume increases by 4 / 80%, the procurement cycle fine-tuning of the selected enterprises and procurement cycle corresponding to 1 / 1 year, 2 or 3 / 2 years, 4 / 3 years 　　The price reduction of the three collections was controlled at 52%-59%, with the highest decrease exceeding 90% (1) pilot compared with the pilot city in 2017 the minimum purchase price of the same drug, the proposed selection price decreased by 52% on average, the highest reduction of 95% (2) alliance procurement compared with the expansion of the area in 2018 the minimum purchase price of the same drug, the proposed selectprice price decreased by 59%, compared with the price of 4 -
7 　　The Opinions on Deepening the Reform of the Medical Security System state that we should give full play to the leading role of centralized band procurement of medicines and medical supplies in deepening the supply-side reform of services, promote the integration of medical insurance, medical and pharmaceutical reform systems, strengthen policy and management coordination, and ensure that the masses receive high-quality and affordable medical services the leading role of centralized procurement foreshadows the succession of collection III, IV, V 　　From the pilot to the collection II, the collection scheme was announced to the results, the time was shortened from 32 days to 22 days, the time was greatly compressed Pilot to the alliance procurement interval of nearly 9 months, and the alliance procurement to the collection II interval of only 3 months, perhaps the original plan in March this year should be announced collection III, affected by the outbreak collection III may be two after the second meeting, the network spread the third batch of collection or will start in July, the specific time, it remains to be seen 　　There is no doubt that from the gradually mature collection rules and the successful implementation of the first batch of the results of the collection, collection III, and even collection IV, V range ratio will be expanded, and even to achieve full coverage According to public data, the number of varieties through consistency evaluation is currently 212, of which 155 varieties have not yet been included in the national drug centralized procurement, it can be seen that the sequel picks or will become their performance highlight moment, in other words, it is only a matter of time before entering the collection 　　The collection is not yet involved in injections, with the "injection consistency evaluation requirements" officially released, injection band quantity procurement is not far away, especially intravenous anti-infective drugs, this area share of public medical institutions procurement amount of 20%, the future will be the focus area of collection 　　From the coverage and use of drug demand, drug variety range, centralized procurement rules, the first year agreed procurement volume and procurement cycle, through the first three gradual collection, the collection mode basically remained stable, the practice has proved that the model can ensure that the masses to obtain high-quality and affordable medical services thus, the author boldly predicted collection III: from the collection of the collection program published to the collection results published or will be less than 20 days, July or will open the third batch of band procurement, more than the year there is hope to start collection IV, the shortlisted varieties may be less than 50, the price decline may remain between 50-60% the centralized procurement of medicine is not new, has gradually become a normal situation in China's pharmaceutical industry, but it is still the focus of the pharmaceutical industry, especially the pharmaceutical Therefore, for the general direction of pharmaceutical enterprises need to adjust the business strategy, the National People's Congress representative, Hengrui Pharmaceutical Chairman Sun Flutter called at the two meetings, "recommended the "drug test data protection implementation measures (provisional)" to be revised, in the protection of the object to increase the protection of improved new drugs, for the general improved new drugs can be given 3 years of data protection, the new indications of which part of the consideration to give 4 years of data protection." "
the future, the collection or will focus on the layout of innovative drugs, step by step to develop improved new drugs, the appropriate amount of imitation of generic drugs And innovation and improvement will become the main theme, high-quality and efficient use of generic drugs in the future of low prices are visible.